Search Results - "BALOW, James E"

Randomized, Controlled Trial of Prednisone, Cyclophosphamide, and Cyclosporine in Lupus Membranous Nephropathy by AUSTIN, Howard A, ILLEI, Gabor G, BRAUN, Michelle J, BALOW, James E

“…Patients with lupus membranous nephropathy (LMN) are at substantial long-term risk for morbidity and mortality associated with protracted nephrotic syndrome,…”
Get full text

Safety and Tolerability of Omalizumab: A Randomized Clinical Trial of Humanized Anti‐IgE Monoclonal Antibody in Systemic Lupus Erythematosus by Hasni, Sarfaraz, Gupta, Sarthak, Davis, Michael, Poncio, Elaine, Temesgen‐Oyelakin, Yenealem, Joyal, Elizabeth, Fike, Alice, Manna, Zerai, Auh, Sungyoung, Shi, Yinghui, Chan, Diana, Carlucci, Philip, Biehl, Ann, Dema, Barbara, Charles, Nicolas, Balow, James E., Waldman, Meryl, Siegel, Richard M., Kaplan, Mariana J., Rivera, Juan

“…Objective Autoreactive IgE antibodies have been implicated in the pathogenesis of systemic lupus erythematosus (SLE). We hypothesize that omalizumab, a…”
Get full text

Chronic granulomatous disease as a risk factor for autoimmune disease by De Ravin, Suk See, MD, PhD, Naumann, Nora, MD, Cowen, Edward W., MD, MHSc, Friend, Julia, MPH, PA-C, Hilligoss, Dianne, RN, MSN, CRNP, Marquesen, Martha, NP, Balow, James E., MD, Barron, Karyl S., MD, Turner, Maria L., MD, Gallin, John I., MD, Malech, Harry L., MD

“…Chronic granulomatous disease (CGD) is characterized by recurrent infections and granuloma formation. In addition, we have observed a number of diverse…”
Get full text

Urinary exosomal transcription factors, a new class of biomarkers for renal disease by Zhou, Hua, Cheruvanky, Anita, Hu, Xuzhen, Matsumoto, Takayuki, Hiramatsu, Noriyuki, Cho, Monique E., Berger, Alexandra, Leelahavanichkul, Asada, Doi, Kent, Chawla, Lakhmir S., Illei, Gabor G., Kopp, Jeffrey B., Balow, James E., Austin, Howard A., Yuen, Peter S.T., Star, Robert A.

“…Urinary exosomes are excreted from all nephron segments and constitute a rich source of intracellular kidney injury biomarkers. To study whether they contain…”
Get full text

The classification of glomerulonephritis in systemic lupus erythematosus revisited by WEENING, Jan J, D'AGATI, Vivette D, FOGO, Agnes B, GINZLER, Ellen M, HEBERT, Lee, HILL, Gary, HILL, Prue, JENNETTE, J. Charles, KONG, Norella C, LESAVRE, Philippe, LOCKSHIN, Michael, LOOI, Lai-Meng, SCHWARTZ, Melvin M, MAKINO, Hirofumi, MOURA, Luiz A, NAGATA, Michio, SESHAN, Surya V, ALPERS, Charles E, APPEL, Gerald B, BALOW, James E, BRUIJN, Jan A, COOK, Terence, FERRARIO, Franco

“…The currently used classification reflects our understanding of the pathogenesis of the various forms of lupus nephritis, but clinicopathologic studies have…”
Get full text

miR-150 Promotes Renal Fibrosis in Lupus Nephritis by Downregulating SOCS1 by HUA ZHOU, HASNI, Sarfaraz A, ILLEI, Gabor G, PEREZ, Paola, TANDON, Mayank, JANG, Shyh-Ing, CHANGYU ZHENG, KOPP, Jeffery B, AUSTIN, Howard, BALOW, James E, ALEVIZOS, Ilias

Get full text

Membranous nephropathy: Pilot study of a novel regimen combining cyclosporine and Rituximab by Waldman, Meryl, Beck, Jr, Laurence H, Braun, Michelle, Wilkins, Kenneth, Balow, James E, Austin, 3rd, Howard A

“…There is broad consensus that high grade basal proteinuria and failure to achieve remission of proteinuria are key determinants of adverse renal prognosis in…”
Get full text

Microarray-based gene expression profiling in patients with cryopyrin-associated periodic syndromes defines a disease-related signature and IL-1-responsive transcripts by Balow, Jr, James E, Ryan, John G, Chae, Jae Jin, Booty, Matthew G, Bulua, Ariel, Stone, Deborah, Sun, Hong-Wei, Greene, James, Barham, Beverly, Goldbach-Mansky, Raphaela, Kastner, Daniel L, Aksentijevich, Ivona

“…To analyse gene expression patterns and to define a specific gene expression signature in patients with the severe end of the spectrum of cryopyrin-associated…”
Get more information

Spectrum of Renal Diseases Associated with Extreme Forms of Insulin Resistance by Musso, Carla, Javor, Edward, Cochran, Elaine, Balow, James E, Gorden, Phillip

“…Diabetic nephropathy is the leading cause of ESRD in the United States. Why the pathogenic mechanisms lead to nephropathy in certain patients with type 1 and 2…”
Get full text

Nephropathy in the context of HIV infection by Balow, James E.

Get full text

Update on scoring and providing evidence basis for assessing pathology in lupus nephritis by Bajema, Ingeborg M, Balow, James E, Haas, Mark, Jayne, David, Lightstone, Liz, Rovin, Brad H, Seshan, Surya V, Fogo, Agnes B

Get more information

miR-150 promotes renal fibrosis in lupus nephritis by downregulating SOCS1 by Zhou, Hua, Hasni, Sarfaraz A, Perez, Paola, Tandon, Mayank, Jang, Shyh-Ing, Zheng, Changyu, Kopp, Jeffery B, Austin, 3rd, Howard, Balow, James E, Alevizos, Ilias, Illei, Gabor G

“…MicroRNAs (miRs) seem to mediate renal fibrosis in several renal diseases, with some miRs having profibrotic effects and others having opposing effects…”
Get full text

Rituximab or Cyclosporine for Membranous Nephropathy by Waldman, Meryl, Austin, Howard A, Balow, James E, Ponticelli, Claudio, Moroni, Gabriella, Fervenza, Fernando C, Cattran, Daniel C

“…To the Editor: Fervenza et al. (July 4 issue) 1 report that rituximab was noninferior to cyclosporine in inducing remission of membranous nephropathy. Although…”
Get full text

Effects of metreleptin on proteinuria in patients with lipodystrophy by Lee, Ho Lim, Waldman, Meryl A, Auh, Sungyoung, Balow, James E, Cochran, Elaine K, Gorden, Phillip, Brown, Rebecca J

“…Patients with lipodystrophy have high prevalence of proteinuria. To assess kidney disease in patients with generalized (GLD) vs partial lipodystrophy (PLD),…”
Get full text

Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open‐label phase I dosage‐escalation study by Illei, Gabor G., Shirota, Yuko, Yarboro, Cheryl H., Daruwalla, Jimmy, Tackey, Edward, Takada, Kazuki, Fleisher, Thomas, Balow, James E., Lipsky, Peter E.

“…Objective To assess the safety of interleukin‐6 receptor inhibition and to collect preliminary data on the clinical and immunologic efficacy of tocilizumab in…”
Get full text

Parathyroid Hormone Resistance and Autoantibodies to the PTH1 Receptor by Mandl, Adel, Burbelo, Peter D, Di Pasquale, Giovanni, Tay, You Sher, Welch, James, Lionakis, Michail S, Rosenzweig, Sergio D, Waldman, Meryl A, Warner, Blake M, Walitt, Brian, Collins, Michael T, Balow, James E, Chiorini, John A, Simonds, William F, Agarwal, Sunita K, Blau, Jenny E, Weinstein, Lee S

“…We describe two cases of acquired parathyroid hormone (PTH) resistance consequent to the development of serum PTH type 1 receptor (PTH1R) autoantibodies, which…”
Get full text

The classification of glomerulonephritis in systemic lupus erythematosus revisited by Weening, Jan J., D'agati, Vivette D., Schwartz, Melvin M., Seshan, Surya V., Alpers, Charles E., Appel, Gerald B., Balow, James E., Bruijn, J.A.N. A., Cook, Terence, Ferrario, Franco, Fogo, Agnes B., Ginzler, Ellen M., Hebert, Lee, Hill, Gary, Hill, Prue, Jennette, J. Charles, Kong, Norella C., Lesavre, Philippe, Lockshin, Michael, Looi, Lai-Meng, Makino, Hirofumi, Moura, Luiz A., Nagata, Michio, ON Behalf of the International Society of Nephrology and Renal Pathology Society Working Group on the Classification Oflupus Nephritis

“…The classification of glomerulonephritis in systemic lupus erythematosus revisited.The currently used classification reflects our understanding of the…”
Get full text

A novel variant affecting the cytoplasmic tail of the FAT1 protocadherin causing coloboma and renal failure: A case report by Vieta-Ferrer, Emile R, Ullah, Ehsan, Blain, Delphine, Christensen, Julie A, Brewer, Carmen C, Balow, James E, George, Aman, Hufnagel, Robert B, Cogliati, Tiziana, Brooks, Brian P

“…Variations in the protocadherin gene have recently been associated with a syndrome that includes coloboma, facial dysmorphism, renal failure, syndactyly, and…”
Get full text

Enzyme Replacement Therapy in Fabry Disease: A Randomized Controlled Trial by Schiffmann, Raphael, Kopp, Jeffrey B, Austin III, Howard A, Sabnis, Sharda, Moore, David F, Weibel, Thais, Balow, James E, Brady, Roscoe O

“…CONTEXT Fabry disease is a metabolic disorder without a specific treatment, caused by a deficiency of the lysosomal enzyme α-galactosidase A (α-gal A). Most…”
Get full text

Glomerular disease: perspectives on maintenance therapy in lupus nephritis by Balow, James E

Get full text